Artificial intelligence is already reshaping how vaccines are discovered, designed, and delivered, compressing timelines that once stretched across a decade or more. An umbrella review of the field found that AI-driven integration of biological data accelerated epitope mapping by months and optimized manufacturing workflows and cold-chain logistics in ways that traditional methods could not match. The technology touches nearly every stage of the vaccine pipeline, from picking the right molecular targets to predicting how a pathogen will mutate next. But the story is more nuanced than the hype suggests, and the gap between a promising computer prediction and a working vaccine remains real.
Finding the Right Targets Faster
The first challenge in building any vaccine is choosing which piece of a pathogen to show the immune system. Traditionally, this meant years of laboratory screening, growing the pathogen in culture, isolating proteins, and testing them one at a time. AI flips the process: algorithms trained on databases of known immune interactions can scan an entire pathogen genome and flag the protein fragments most likely to trigger a strong immune response. These fragments, called epitopes, are the molecular bullseyes a vaccine needs to hit.
Deep learning models have proven particularly effective at this. A convolutional neural network called DeepImmuno, benchmarked against validated peptide collections from dengue virus, cancer neoantigens, and SARS-CoV-2, outperformed multiple traditional machine learning approaches and adapted well to both small and large datasets.1Briefings in Bioinformatics. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity Another model, DeepNetBim, combined binding prediction with immunogenicity prediction using a network-based architecture and achieved an accuracy score above 93% for predicting how well peptides bind to immune-recognition molecules, outperforming eleven existing models on benchmark datasets.2PubMed Central. DeepNetBim: deep learning model for predicting HLA-epitope interactions based on network analysis by harnessing binding and immunogenicity information
A more recent system called VenusVaccine, which uses a dual-attention deep learning architecture, surpassed traditional epitope prediction methods by five to ten percentage points in standard performance metrics, with accuracy scores frequently exceeding 0.90. Its predictions were validated by confirming known and novel vaccine antigens in the published literature.3Nature (npj Vaccines). AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development The practical upshot is that researchers can now narrow a list of thousands of candidate peptides down to a handful of strong leads before touching a pipette, saving months of wet-lab work.
Designing Stable Vaccine Proteins
Identifying a good target is only half the battle. Many viral surface proteins are shapeshifters: they change conformation before and after fusing with a human cell, and the “prefusion” form is usually the one you want in a vaccine because it best mimics what the immune system sees during natural infection. The problem is that prefusion proteins are often fragile and tend to collapse into their postfusion shape, making them useless as vaccine components. AI is now helping engineers lock these proteins into the right configuration.
For Epstein-Barr virus, researchers used AI tools called ThermoMPNN and ProScan to predict which amino acid swaps would stabilize the gB surface protein. The approach identified a small set of substitutions that produced a variant achieving complete trimer formation and holding its prefusion shape, as confirmed by electron microscopy.4Nature Communications. Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen A similar strategy was applied to the human coronavirus OC43 spike protein using an AI tool called ReCaP. Rationally combined substitutions guided by the model produced markedly improved expression levels and thermal stability, a key result because a more stable antigen means a vaccine that holds up better during storage and transport.5PLOS Pathogens. AI-guided prefusion stabilization of the human coronavirus OC43 spike protein enables universal embecovirus antigen design
These examples hint at a broader possibility: if AI can stabilize surface proteins from one virus, the same tools can be applied across entire viral families, accelerating the design of antigens for pathogens that have resisted traditional vaccine approaches for decades.
Making mRNA Vaccines More Potent
The COVID-19 pandemic proved that mRNA vaccines can go from sequence to shot in record time, but the underlying mRNA molecules are still tricky to optimize. Small changes in how a coding sequence is arranged, or in the regulatory regions flanking it, can dramatically change how much protein a cell produces and how long the mRNA lasts before degrading. Optimizing these sequences by hand is like trying to compose a novel one letter at a time while respecting a huge set of biochemical constraints.
A generative AI model called GEMORNA, built on transformer architectures tailored for mRNA, tackles this by designing entire coding sequences and untranslated regions from scratch. In lab tests, GEMORNA-designed mRNAs produced up to a 41-fold increase in protein expression compared with an already-optimized benchmark. When applied to a therapeutic context, it achieved up to a 15-fold enhancement in human erythropoietin expression and substantially boosted antibody levels in mice receiving a COVID vaccine construct.6PubMed. Deep generative models design mRNA sequences with enhanced translational capacity and stability The significance is not just more protein per dose; higher expression could mean lower doses work just as well, reducing side effects and stretching vaccine supply further.7PubMed Central. AI-powered design accelerates the development of mRNA therapeutics
Optimizing How Vaccines Reach Cells
An mRNA vaccine is only as good as its delivery vehicle. The lipid nanoparticles that carry mRNA into cells are complex mixtures of fats, cholesterol, and helper molecules whose proportions affect everything from how efficiently cells absorb the payload to how the nanoparticle behaves during storage. Exploring this chemical space experimentally is slow and expensive because there are thousands of possible formulations. Machine learning models trained on existing formulation data can predict which combinations are likely to work best, reducing the number of experiments needed and deepening understanding of how formulation inputs map to functional outputs.8PubMed. Review of machine learning for lipid nanoparticle formulation and process development
The same logic extends to adjuvants, the immune-boosting ingredients added to many non-mRNA vaccines. Traditional adjuvant discovery relied heavily on trial and error. AI-driven screening can now help identify novel adjuvant candidates with favorable safety and efficacy profiles by predicting molecular interactions before any compounds are synthesized.9PubMed. Leveraging artificial intelligence in vaccine development: A narrative review Taken together, AI is streamlining not just what goes into a vaccine but how it physically reaches the immune system.
Personalized Cancer Vaccines
Cancer vaccines represent one of the most ambitious applications of AI in immunology. Unlike infectious-disease vaccines, which target a pathogen shared by everyone, cancer vaccines need to target neoantigens: mutated proteins unique to a patient’s tumor. Each person’s cancer carries a different mutational fingerprint, so the vaccine has to be custom-built. The computational challenge is immense. You need to sequence the tumor, identify which mutations produce proteins that look foreign to the immune system, predict which of those will actually trigger a T-cell response, and do all of this fast enough for the patient to benefit.
Machine learning algorithms are well suited to this because they can handle the multidimensional nature of genomic, proteomic, and immunological data simultaneously, extracting neoantigen features that would be invisible to manual analysis.10PubMed Central. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy AI workflows are increasingly integrated into the neoantigen prioritization pipeline to support more reproducible decisions about which mutations to include in a patient’s vaccine.11PubMed Central. Artificial intelligence for translational personalized neoantigen cancer vaccine development Several personalized cancer vaccines are now in clinical trials, with AI-based prediction at their core, though the field is still early and large-scale efficacy data are limited.
Predicting Future Variants Before They Emerge
One of the more striking applications of generative AI in vaccinology is forecasting how a virus might mutate in the future. During the COVID-19 pandemic, new variants repeatedly outpaced vaccine updates. A model called SpikeGPT2, fine-tuned on SARS-CoV-2 spike protein sequences deposited before May 2021, achieved roughly 89% accuracy in predicting the next amino acid at each position and successfully flagged substitutions that appeared in real viral sequences deposited after May 2021, sequences the model had never seen. It also predicted novel variants not yet in any database. Binding analysis of the generated substitutions identified several that were predicted to increase transmissibility and evade therapeutic antibodies, including N501Y, a mutation already known to boost viral spread.12bioRxiv. A deep generative model of the SARS-CoV-2 spike protein predicts future variants
The practical implication is tantalizing: if similar models can reliably predict which mutations are coming, vaccine designers could begin updating formulations before a new variant has even started spreading. That kind of preemptive approach could turn the pandemic response model from reactive to proactive. The caveat, of course, is that predicting a plausible mutation and predicting which mutation will dominate globally are different problems, and the second one involves epidemiological and ecological factors that no protein-language model currently captures.
Generative Models for Antibody and Immune Design
Vaccine design is not the only area where generative AI is making waves. The same class of models is being applied to design therapeutic antibodies, molecules that can be given as treatments or used as research tools to understand how vaccines work. Generative diffusion models, the same family of algorithms behind image-generation tools, are being adapted to design antibody structures from scratch or to optimize the binding regions of existing antibodies.13PubMed Central. AI-driven antibody design with generative diffusion models: current insights and future directions
On the systems-level side, AI and deep learning are helping researchers model entire immune responses rather than isolated molecular interactions. This includes integrating multi-omics data to better classify patient diseases, refining the selection of both B-cell and T-cell targets, and deepening understanding of immune regulation and immune evasion pathways.14PubMed Central. Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow In one concrete example, machine learning models trained on blood gene-expression data successfully predicted the magnitude of antibody responses to a two-dose Ebola vaccine, highlighting how early immune signals captured through systems-level analysis can forecast downstream vaccine-induced immunity.15PubMed Central. Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine If you can predict who will respond well and who will not, you can start tailoring dosing schedules or adjuvant choices to individual patients.
Simulating Clinical Trials Before Running Them
Clinical trials are the most expensive and time-consuming part of getting a vaccine to market. AI-based in silico clinical trials aim to simulate parts of that process computationally, automating trial design, optimizing patient selection, and modeling immune responses at a scale and speed that physical trials cannot match.16ChemRxiv. Artificial Intelligence Based in silico Clinical Trials for Vaccines The goal is not to replace human trials entirely; regulators will still require real-world safety and efficacy data. Rather, simulations can help identify the most promising vaccine candidates and trial designs before a single participant is enrolled, reducing the number of candidates that fail late in development and lowering costs.
Think of it as a screening filter. A pharmaceutical company might have several antigen candidates, different adjuvant combinations, and multiple dosing schedules. Running a full trial for every permutation is impractical. Simulations can predict which combinations are most likely to succeed, allowing researchers to enter human trials with higher confidence. The technology is still maturing, and no regulator has yet accepted in silico trial results as a substitute for phase III data, but the direction is clear.
How Often Do AI Predictions Actually Work in the Lab?
This is where the story gets honest. AI predictions still fail at meaningful rates when tested experimentally, and the success rate varies dramatically depending on the pathogen and the prediction method. In one evaluation of 118 AI-selected SARS-CoV-2 T-cell epitopes tested across diverse human cohorts, roughly 63% triggered measurable T-cell responses, with 24 peptides proving to be broadly immunodominant across populations. A separate deep-learning study identified conserved SARS-CoV-2 T-cell epitopes, formulated them into a DNA vaccine, and found that 15 out of 17 predicted epitopes worked in mice, protecting vaccinated animals from lethal infection even without neutralizing antibodies.3Nature (npj Vaccines). AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development
Those numbers sound encouraging, but they are not universal. For Ebola virus, experimental validation of computationally predicted epitopes in transgenic mice found that only about 30 to 50% of predicted peptides actually triggered the expected immune response.3Nature (npj Vaccines). AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development That is still a vast improvement over random screening, but it means AI predictions are a starting point for lab validation, not a replacement for it. The hit rate depends on the pathogen, the prediction approach, and the experimental system used for testing.
Data Gaps and Biases That Limit the Technology
The performance of any AI model is only as good as the data it learns from, and in vaccinology the available data are biased in important ways. Epitope datasets are heavily skewed toward a handful of well-studied pathogens like influenza and SARS-CoV-2, while diseases that disproportionately affect lower-income countries have far fewer examples in the training data. Similarly, the immunological data available overrepresent common genetic variants in immune molecules, meaning the models may perform well for people of European descent but less reliably for populations carrying rarer genetic variants.17npj vaccines. AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development
There is also a subtle but consequential problem with how “negative” data are defined. When a peptide is labeled as a non-epitope in a training set, that usually means nobody has tested it rather than someone tested it and it failed. This ambiguity can cause models to over-predict epitopes, flagging too many candidates as promising and making downstream experimental validation more expensive.17npj vaccines. AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development Until training data expand to cover more pathogens, more populations, and more rigorously confirmed negatives, AI vaccine models will carry these blind spots.
AI in the Vaccine Supply Chain
AI’s role does not end once a vaccine is designed. Getting vaccines from factory to arm involves a fragile cold chain, and temperature excursions during transport and storage are a leading cause of vaccine waste, especially in tropical climates. An umbrella review found that AI-driven predictive analytics are already optimizing manufacturing workflows and temperature-controlled logistics.18PubMed Central. Artificial intelligence in vaccine research and development: an umbrella review
A more specific platform concept integrates AI with real-time sensor data from shipping containers and clinic refrigerators. At the formulation stage, graph neural networks simulate how a vaccine degrades over time, helping designers choose stabilizing ingredients. During distribution, sensor telemetry enables dynamic rerouting of batches away from routes experiencing temperature problems. At the clinic, adaptive expiry labeling adjusts shelf-life estimates based on actual storage conditions rather than conservative worst-case assumptions, reducing wastage from premature disposal.19Intelligent Systems with Applications. AI-predictive vaccine stability: a systems biology framework to modernize regulatory testing and cold chain equity For regions where a large fraction of vaccine doses are lost to cold-chain failures, this kind of optimization could be as impactful as designing a better antigen.
Where Reverse Vaccinology Meets Large Language Models
Reverse vaccinology, the idea of starting from a pathogen’s genome rather than from the whole organism, has been around since the early 2000s and was originally used to develop the meningococcal B vaccine. AI has supercharged this approach. Large language models and generative AI are now being explored for their ability to scan genomes, predict protein functions, and rank vaccine candidates with greater efficiency and accuracy than older bioinformatics pipelines.20Informatics in Medicine Unlocked. Generative AI and large language models: A new frontier in reverse vaccinology
The appeal of language models in this context is that protein sequences share structural similarities with natural language: they are strings of characters (amino acids) whose meaning depends on context and order. Models originally designed to predict the next word in a sentence can be repurposed to predict the next amino acid in a protein, or to generate entirely new protein sequences with desired properties. This is the same principle behind SpikeGPT2’s variant-prediction work and GEMORNA’s mRNA design. The trend across the field is a convergence of generative AI techniques originally developed for text, images, and audio into the molecular design space, and vaccinology is one of the clearest beneficiaries.
What remains uncertain is how these tools will interact with regulatory frameworks. Drug regulators have well-established processes for evaluating vaccines made by traditional methods. AI-designed vaccines raise new questions: how do you validate a molecule that was generated by a model rather than discovered in nature? How much experimental data is enough when the candidate was computationally optimized from the start? These questions do not have settled answers yet, and the regulatory landscape is evolving alongside the technology itself.